Medtronic Raises 2027 Projections Amid Surge in Heart Device Demand
Medtronic lifts its 2027 revenue forecasts, driven by robust heart device demand and strategic investments.
Medtronic has revised its fiscal 2027 forecasts upward, citing increased demand for its heart devices used in complex cardiovascular procedures. The company now expects annual organic revenue growth to range between 7.25% and 7.75%, an increase from the previously projected 6.75% to 7.25% range.
Strategic Investments in Heart and Robotic Technologies
In a strategic move to bolster its cardiovascular segment, Medtronic announced an $80 million investment in Pi-Cardia, a heart-valve repair device maker, with an option to acquire the company for $210 million. Additionally, Medtronic has invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select markets outside the United States.
Geoff Martha, CEO of Medtronic, emphasized the importance of these investments, stating that the global penetration of soft tissue robotic surgery remains under 1% in emerging markets. Cornerstone's Sentire device is seen as complementary to Medtronic's Hugo surgical robot, expanding the company's footprint in high-growth medtech sectors.
Financial Performance and Market Outlook
Medtronic reported quarterly sales in its cardiovascular segment surged by 19.5% to $3.93 billion, driven by an 88% growth in its pulsed field ablation portfolio, which treats irregular heart rhythms. The company posted an adjusted quarterly profit of $1.45 per share on revenue of $9.76 billion, surpassing analyst expectations of $1.39 per share on $9.55 billion in sales, according to LSEG data.
Chief Financial Officer Thierry Pieton noted that the company received tariff refunds that nearly offset duties paid during the quarter. However, Medtronic has not factored in potential future refunds into its financial outlook.
CEO Geoff Martha highlighted the company's steady acquisition strategy, focusing on high-growth segments with substantial patient pools. "We're prioritizing the higher growth segments of medtech that we have confidence will be large segments," Martha stated during a post-earnings call.